Clay Siegall is the President, CEO and Chairman of the Board for Seattle Genetics. He co-founded Seattle Genetics in 1998 with the goal of developing antibody drug conjugates (ADCs) for cancer treatment. ADCs are valuable in cancer treatment as they directly target cancer cells, while not affecting other healthy cells, thus avoiding some of the more debilitating effects of other cancer treatments such as chemotherapy.
Dr. Siegall is more than just a businessman, but a dedicated science with more than 20 years experience in cancer research including a PhD from George Washington University. Before co-founding Seattle Genetics Dr. Siegall worked with Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 and the National Cancer Institute, National Institutes of Health from 1988 to 1991.
Under Dr. Siegall’s leadership Seattle Genetics gained approval from the FDA in 2011 to market the first commercially available ADC product ADCETRIS. Now, this treatment is available in 60 countries worldwide fighting cancer globally.
Seattle Genetics hold its mission as “Improving the lives of people with cancer through innovative and empowered antibody-based therapies” via more than 800 employees who work at the company. According to glassdoor.com 88% of employees approve of CEO Clay Siegall and Seattle Genetics received a 3.7 star rating as a company.
Future projects of Seattle Genetics include initiation of Phase 1 Trial of SGN-CD352A for Patients with Relapsed or Refractory Multiple Myeloma, a disease which affects more than 124,000 people world-wide. The phase 1 clinical study will enroll approximately 75 relapsed or refractory patients.